Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.

[1]  Jun Zou,et al.  Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor , 2022, Nature Communications.

[2]  Lijuan Xu,et al.  Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease. , 2022, Journal of medicinal chemistry.

[3]  P. Fu,et al.  Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors. , 2022, European journal of medicinal chemistry.

[4]  Xiaobing Wang,et al.  Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment. , 2021, Pharmacology & therapeutics.

[5]  Wannian Zhang,et al.  Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors. , 2021, European journal of medicinal chemistry.

[6]  Junying Yuan,et al.  Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target , 2020, Nature Reviews Drug Discovery.

[7]  P. Vandenabeele,et al.  Inhibitors Targeting RIPK1/RIPK3: Old and New Drugs. , 2020, Trends in pharmacological sciences.

[8]  Chun-lin Zhuang,et al.  Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives. , 2020, Journal of medicinal chemistry.

[9]  Xiaohu Zhang,et al.  Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis , 2019, Cell Death & Disease.

[10]  P. A. Harris,et al.  Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer , 2019, ACS medicinal chemistry letters.

[11]  A. Degterev,et al.  Targeting RIPK1 for the treatment of human diseases , 2019, Proceedings of the National Academy of Sciences.

[12]  B. Lamb,et al.  Inflammation as a central mechanism in Alzheimer's disease , 2018, Alzheimer's & dementia.

[13]  M. Yoshikawa,et al.  Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. , 2018, Journal of medicinal chemistry.

[14]  P. A. Harris,et al.  Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers , 2017, Pharmacology research & perspectives.

[15]  J. Levin,et al.  RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease , 2017, Proceedings of the National Academy of Sciences.

[16]  P. Vandenabeele,et al.  Sibiriline, a new small chemical inhibitor of receptor‐interacting protein kinase 1, prevents immune‐dependent hepatitis , 2017, The FEBS journal.

[17]  Michelle C. Schaeffer,et al.  Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. , 2017, Journal of medicinal chemistry.

[18]  Xiaodong Wang,et al.  Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. , 2017, Journal of medicinal chemistry.

[19]  J. Bertin,et al.  RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4. , 2016, Immunity.

[20]  Deepak Bandyopadhyay,et al.  DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors. , 2016, Journal of medicinal chemistry.

[21]  M. Pasparakis,et al.  RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis , 2014, Nature.

[22]  Xiaodong Wang,et al.  Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. , 2014, Molecular cell.

[23]  Junying Yuan,et al.  Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death , 2013, Nature Reviews Molecular Cell Biology.

[24]  P. Vandenabeele,et al.  Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models , 2012, Cell Death and Disease.

[25]  P. Vandenabeele,et al.  TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation , 2012, Cell Death and Differentiation.

[26]  Xiaodong Wang,et al.  Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase , 2012, Cell.

[27]  T. Vanden Berghe,et al.  RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. , 2011, Immunity.

[28]  F. Chan,et al.  Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation , 2009, Cell.

[29]  Tao Wang,et al.  Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α , 2009, Cell.

[30]  Alexei Degterev,et al.  Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.

[31]  A. Degterev,et al.  Structure-activity relationship study of tricyclic necroptosis inhibitors. , 2007, Journal of medicinal chemistry.

[32]  A. Degterev,et al.  Structure-activity relationship study of novel necroptosis inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[33]  Alexei Degterev,et al.  Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.